Jeff Eiseman
Contributor since: 2013
Latest Articles
Tonix: Reinforcing And Extending A Positive Zacks Report On Treating PTSD
Why Tonix's Upward Trajectory Will Continue: Interpretation Of Recent Developments
Tonix's Findings About Patient Subgroups Can Mislead: How Investors Can Tell What's Real
What The Future Holds For Tonix
PharmAthene's Worth: The NPV Of Lady Justice's Judgment And Winning A $1.25 Billion NIH Contract
The Third Time's A Charm: How Tonix's Success With Its PTSD Trial Relates To Its Fibromyalgia Trial
2 Extraordinary Value Bargains, Part I: Galloping Toward PharmAthene And Tonix's Red Letter Days
How Will Hillary Clinton's Drug Price Limit Plan Impact Tonix?
Despite SIGA's Claim, The Supreme Court Will Speak Soon And PharmAthene Will Fare Well
Tonix: Its Blockbuster Headache Remedy, Two 2015 Catalysts, & Two Post-Offering Valuations
Tonix Pharmaceuticals: Four Data-Based Valuations Of A Deeply Underappreciated Pharmaceutical Company
The Cloud's Silver Lining: Beyond Tonix's Missed Phase 2 Primary Endpoint For Fibromyalgia
Properly Treating Costs: Re-Evaluating The MannKind And Sanofi Partnership
What The Judge's Award Means For PharmAthene's Value/Share: A Data-Based Analysis
While We Wait For A Ruling In SIGA V. PharmAthene, One More Round With G. Hudson
PharmAthene Vs. SIGA: Rebutting G. Hudson's 'Potential Award' Article
Do MannKind Insiders Harbor Doubts? Three Authors Say 'Yes'; The Data Say 'No'
How The Judge Will Arrive At A Remedy In SIGA V. PharmAthene
Reconciling Rival Views Of Afrezza, And How To Play The Post-AdCom Surge
What The FDA Document Says About Afrezza: Implications For FDA Approval
Fear, Greed, And Prudent Risks: A Clarion Call To The Keepers Of The MannKind Flame
How Will Subconscious Issues Influence FDA AdCom Voting On Afrezza?
MannKind Catalysts: Insights About Diabetes Care Metrics And Long-Term Complications
PharmAthene Is A Bargain: Significance Of Recent Legal, Pipeline, And Merger Developments
How PharmAthene And Theraclone's Assets Will Enhance Shareholder Value
Revelations From PharmAthene's Legal Brief: Implications For Investors
How An Improved Damages Award Against SIGA Would Affect PharmAthene's Valuation
Why PharmAthene Will Win Its Suit With SIGA And How Much It Will Collect
SIGA Technologies Vs. PharmAthene: A Comprehensive Analysis Of The Legal Issues